Ryman Healthcare Limited
RHCGFOTCHealthcare● Active
$1.41
+$0.00(+0.00%)
Market Cap$1.4B
P/E Ratio—
52W High$3.11
52W Low$1.21
Ryman Healthcare Limited (RHCGF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RHCGF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 26, 2026EPS Actual
-$0.07
Revenue
$0.24B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 26, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
RHCGF reports quarterly as a OTC-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | May 26, 2026 | — | -$0.07 | — | $0.24B | — | — |
| — Q4 FY2025 | Nov 25, 2025 | — | -$0.03 | — | $0.23B | $0.23B | -2.6% |
| — Q2 FY2025 | May 25, 2025 | — | -$0.43 | — | $0.21B | $0.35B | -40.2% |
| — Q2 FY2025 | May 25, 2025 | — | -$0.20 | — | $0.11B | — | — |
| ▲ Q4 FY2024 | Nov 27, 2024 | $0.06 | $0.08 | +30.6% | $0.22B | $0.30B | -24.4% |
| ◌ Q3 FY2024 | Jul 25, 2024 | — | — | — | — | — | — |
| — Q2 FY2024 | May 26, 2024 | — | -$0.16 | — | $0.22B | $0.34B | -35.4% |
| — Q2 FY2024 | May 26, 2024 | — | -$0.08 | — | $0.12B | $0.34B | -65.7% |
Q2 FY2026
May 26, 2026
EPS Actual
-$0.07
EPS Est.
—
EPS Surpr.
—
Revenue
$0.24B
Q4 FY2025
Nov 25, 2025
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.23B
Q2 FY2025
May 25, 2025
EPS Actual
-$0.43
EPS Est.
—
EPS Surpr.
—
Revenue
$0.21B
Q2 FY2025
May 25, 2025
EPS Actual
-$0.20
EPS Est.
—
EPS Surpr.
—
Revenue
$0.11B
Q4 FY2024
Nov 27, 2024Beat
EPS Actual
$0.08
EPS Est.
$0.06
EPS Surpr.
+30.6%
Revenue
$0.22B
Q3 FY2024
Jul 25, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 26, 2024
EPS Actual
-$0.16
EPS Est.
—
EPS Surpr.
—
Revenue
$0.22B
Q2 FY2024
May 26, 2024
EPS Actual
-$0.08
EPS Est.
—
EPS Surpr.
—
Revenue
$0.12B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 26, 2026 | — | $1.41 | $1.41 | +0.00% |
| — Q4 FY2025 | Nov 25, 2025 | — | $1.75 | $1.75 | +0.00% |
| — Q2 FY2025 | May 25, 2025 | — | $1.41 | $1.41 | +0.00% |
| — Q2 FY2025 | May 25, 2025 | — | $1.41 | $1.41 | +0.00% |
| ▲ Q4 FY2024 | Nov 27, 2024 | +30.6% | $2.61 | $2.61 | +0.00% |
| — Q2 FY2024 | May 26, 2024 | — | $3.35 | $2.22 | -33.73% |
| — Q2 FY2024 | May 26, 2024 | — | $3.35 | $2.22 | -33.73% |
| ▲ Q3 FY2023 | Sep 30, 2023 | +13.1% | $3.62 | $3.62 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 26, 2026
EPS Beat/Miss
—
Price Before
$1.41
Price After
$1.41
Q4 FY2025+0.00%
Report Date
Nov 25, 2025
EPS Beat/Miss
—
Price Before
$1.75
Price After
$1.75
Q2 FY2025+0.00%
Report Date
May 25, 2025
EPS Beat/Miss
—
Price Before
$1.41
Price After
$1.41
Q2 FY2025+0.00%
Report Date
May 25, 2025
EPS Beat/Miss
—
Price Before
$1.41
Price After
$1.41
Q4 FY2024+0.00%
Report Date
Nov 27, 2024
EPS Beat/Miss
+30.6%
Price Before
$2.61
Price After
$2.61
Q2 FY2024-33.73%
Report Date
May 26, 2024
EPS Beat/Miss
—
Price Before
$3.35
Price After
$2.22
Q2 FY2024-33.73%
Report Date
May 26, 2024
EPS Beat/Miss
—
Price Before
$3.35
Price After
$2.22
Q3 FY2023+0.00%
Report Date
Sep 30, 2023
EPS Beat/Miss
+13.1%
Price Before
$3.62
Price After
$3.62
Avg Beat Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move-33.73% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RHCGF ends December
Ryman Healthcare Limited (RHCGF) most recently reported earnings on May 26, 2026 for Q2 FY2026, posting EPS of $-0.07 (in line with the analyst consensus of —). RHCGF has beaten EPS estimates for 2 consecutive quarters. The next RHCGF earnings date is expected around September 1, 2026.
Each quarter, investors track RHCGF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RHCGF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RHCGF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RHCGF earnings · 4 questionsRyman Healthcare Limited's next earnings report is expected around September 1, 2026. RHCGF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RHCGF historically reports after market close (AMC).
RHCGF earnings datewhen is RHCGF earningsRHCGF next earnings datewhen does RHCGF report earningsRHCGF earnings calendar
▸ Source: FMP · Ryman Healthcare Limited SEC filings · US GAAP · Ryman Healthcare Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026